Cargando…
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, the only biologic drugs approved for HS are adalimumab, an anti-tumor necrosis factor (TNF)-α drug, authorized in 2015, and secukinumab, recently licensed. The management of this condition is...
Autores principales: | Martora, Fabrizio, Scalvenzi, Massimiliano, Battista, Teresa, Fornaro, Luigi, Potestio, Luca, Ruggiero, Angelo, Megna, Matteo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516125/ https://www.ncbi.nlm.nih.gov/pubmed/37745273 http://dx.doi.org/10.2147/CCID.S418748 |
Ejemplares similares
-
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022) -
Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023) -
Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021) -
Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023) -
Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)